Key Takeaways:

  • The FDA approved Foundayo (orforglipron) on Wednesday, making it the second GLP-1 pill for weight loss
  • Unlike the Wegovy pill, Foundayo can be taken at any time of day without food or water restrictions
  • Pricing starts at $149 per month for self-pay and $25 per month for those with commercial insurance
  • Clinical trials showed an average weight loss of 12% over 72 weeks on the highest dose

The weight loss medication landscape has become more competitive with a new FDA approval. The US Food and Drug Administration approved Foundayo (orforglipron) on Wednesday, adding a second GLP-1 pill option to the rapidly growing arsenal of obesity therapies. The orforglipron pill is made by Eli Lilly, which also sells the GLP-1 drugs Zepbound for obesity and Mounjaro for diabetes.

What makes this approval particularly significant? The FDA reviewed the Foundayo application in only 50 days under a Commissioner's National Priority Voucher pilot program, making it the fastest approval of a new molecular entity since 2002. Typically, new drug approvals take at least six to 10 months.

A More Flexible GLP-1 Option

Foundayo is coming to market months after the FDA approved the pill form of Novo Nordisk's injectable obesity drug Wegovy. But Eli Lilly is positioning its pill as a clear improvement over the competition. Lilly says Foundayo represents an advance because, unlike the Wegovy pill, it can be taken at any time of day and without restrictions on food and water.

This isn't marketing spin — it addresses a real barrier to treatment adherence. The oral Wegovy pill requires a 30-minute waiting period after consumption before eating, while Foundayo can be taken at any time of day, with or without food, and without water restrictions, which may make it a more convenient option for many people.

Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018.

Clinical Results Show Promise

The efficacy data shows encouraging results, though not quite at the level of injectable options. In a trial supporting approval, people on the highest dose of Foundayo lost an average of 12% of their body weight over 72 weeks, compared with 0.9% for people taking a placebo. More specifically, participants taking the 36 mg dose lost an average of 27.3 pounds (12.4%), compared with 2.2 pounds (0.9%) with the placebo.

For context, the injectable drugs have produced weight loss in trials of more than 20%, while Novo Nordisk said the Wegovy pill showed average weight loss of up to 17% on the highest dose in trials. While Foundayo may not match the most potent injectables, it offers a middle ground for people seeking oral convenience.

An interesting feature of Foundayo is its potential role in weight maintenance. Lilly has also tested what happens when people who've lost weight with an injectable medicine switch to Foundayo, finding that it helped with weight maintenance.

Affordable Pricing Strategy

Eli Lilly is clearly focused on making Foundayo accessible across different insurance situations. Eligible people with commercial insurance may pay as little as $25 per month with the Foundayo savings card, while individuals opting for self-pay can access Foundayo starting at $149 per month for the lowest dose.

For Medicare beneficiaries, eligible Medicare Part D individuals may be able to get Foundayo for $50 per month, beginning as soon as July 1, 2026. This represents a significant departure from the typical high costs associated with brand-name GLP-1 medications. If you're comparing costs across different options, our cost guide can help you understand all available pricing programs.

The rapid availability is also noteworthy. Foundayo will be available via LillyDirect, with prescriptions accepted immediately and shipping beginning April 6, followed shortly after by broad availability through U.S. retail pharmacies and telehealth providers.

Intensifying Market Competition

Lilly will introduce Foundayo only about three months behind Novo Nordisk's Wegovy pill, setting the stage for the next battle between the rival drugmakers in the next frontier for GLP-1 drugs. The competition is already showing results — early demand for Novo's Wegovy pill has been stronger than expected, with Novo reporting more than 600,000 prescriptions in March.

It's a race Lilly is currently winning in the overall GLP-1 market, as Mounjaro earned $22.965 billion in sales last year, compared to Ozempic's $20.1 billion. The addition of Foundayo to Lilly's portfolio could further solidify their position.

David Ricks, chair and CEO of Lilly, notes that fewer than one in ten people who could benefit from a GLP-1 therapy are currently taking one, and are held back by access barriers, stigma, and the complexity of existing treatment options. "We believe Foundayo can help level the playing field for those living with obesity or who are overweight and living with weight-related complications," said Ricks.

What This Means for You

If you've been considering GLP-1 treatment but have been hesitant about weekly injections or the strict timing requirements of the first oral option, Foundayo represents a significant step forward in convenience and flexibility. The ability to take it anytime without food restrictions removes a major barrier that has complicated adherence for many people.

The pricing structure also opens doors for people who may not have had affordable access before. At $149 per month for the starting dose, it's positioned as a more accessible option than many existing treatments. For those with insurance, the $25 copay with Lilly's savings card makes it even more affordable.

If you're interested in exploring GLP-1 medications for weight management, you now have more options than ever. Consider speaking with providers through telehealth platforms or finding a local clinic to discuss whether Foundayo might be right for your situation. The convenience factor alone could make this an attractive option for busy lifestyles where timing medication around meals has been challenging.

The approval of Foundayo represents more than another treatment option — it signals a shift toward more user-friendly GLP-1 medications that can fit into real life without complicated restrictions. As competition increases, we can expect continued improvements in both convenience and affordability across the entire category.